Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biotech Develops Antagonists for Protein Tied to Neurodegenerative Diseases
News Update

Share on Stocktwits


ProMIS Neurosciences' antagonists prevent dysfunctional protein aggregation.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it developed antagonists against the receptor for activated protein kinase C 1 (RACK1), which prevent aggregation of normal brain protein and related neuronal dysfunction that lead to neurodegenerative diseases.

RACK1, an essential protein for normal cell function, is involved in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Thus, using ProMIS' receptors to target RACK1 could play a role in treating those diseases.

"Researchers have identified RACK1 as a promising target for neurodegenerative diseases because it interacts with other physiologically important proteins including TAR DNA-binding protein 43 and fused in sarcoma, an RNA-binding protein. Both are implicated in the development of ALS," the release explained.

"The development of novel antagonists against RACK1 demonstrates the versatility of our proprietary drug discovery and development platform," stated Dr. Elliot Goldstein, ProMIS CEO. "We're using our unique technology to develop not only antibodies and other antagonists for neurodegenerative diseases, including new intrabodies that are ideal for intracellular vectorization, but also a reliable and accurate antibody test for Covid-19. Today's news is another example of how we continue to expand the utility of our platform to address a broad range of diseases in unique and highly differentiated ways."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe